Skip to main content
padlock icon - secure page this page is secure

Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations

Buy Article:

Price: $63.00 + tax (Refund Policy)

Background: We report a comprehensive overview of current Chronic Obstructive Lung Disease (COPD) therapies and discuss the development of possible new pharmacological approaches based on “new” knowledge. Specifically, sensitivity/resistance to corticosteroids is evaluated with a special focus on the role of gene mutations in drug response.

Objective: Critically review the opportunities and the challenges occurring in the treatment of COPD.

Conclusion: Findings from “omics” trials should be used to learn more about biologically targeted drugs, and to select more specific drugs matching patient’s distinctive molecular profile. Specific markers of inflammation such as the percentage of eosinophils are important in determining sensitivity/resistance to corticosteroids. Specific gene variations (Single nucleotide polymorphisms: SNPs) may influence drug sensitivity or resistance.Clinicians working in a real-world need to have a suitable interpretation of molecular results together with a guideline for the treatment and recommendations. Far more translational research is required before new results from omics techniques can be applied in personalized medicine in real-world settings.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: COPD; Classical-therapy; SNPs; complexity; eosinophils; personalized-medicine; real-life analysis; systems approaches

Affiliations: 1: Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy. 2: Unit of Clinical and Molecular Epidemiology, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy. 3: Unit of Pulmonary Rehabilitation, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy. 4: Scientific Direction, IRCCS "San Raffaele Pisana" Via di Valcannuta, 247, I-00166 Rome, Italy.

Appeared or available online: September 6, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more